Cargando…
Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial
BACKGROUND: A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 %...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595052/ https://www.ncbi.nlm.nih.gov/pubmed/26438179 http://dx.doi.org/10.1186/s12871-015-0115-8 |
_version_ | 1782393525915090944 |
---|---|
author | Zaballos, Matilde Bastida, Emilia Agustí, Salomé Portas, Maite Jiménez, Consuelo López-Gil, Maite |
author_facet | Zaballos, Matilde Bastida, Emilia Agustí, Salomé Portas, Maite Jiménez, Consuelo López-Gil, Maite |
author_sort | Zaballos, Matilde |
collection | PubMed |
description | BACKGROUND: A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 % (EC(50)) of adults necessary for successful insertion of the LMA-Supreme™ and to examine remifentanil’s effect on propofol requirements. METHODS: Fifty-eight elective patients (aged 18–60 years; ASA (American Society Anaesthesiologists) physical status classification I and II) scheduled for day surgery were randomly assigned to one of two groups: propofol with saline or propofol with remifentanil. Anaesthesia was induced by target-controlled infusion according to predetermined effect-site concentrations of propofol and remifentanil (5 ng.mL(−1)). The EC(50) was calculated using Dixon’s up-and-down method. Ten minutes following drug administration, LMA-Supreme™ insertion was attempted without the use of muscle relaxant drugs. RESULTS: In the propofol + saline group, the EC(50) of propofol required for LMA-Supreme™ insertion was 6.32 ± 0.67 μg.mL(−1) (95 % CI, 5.69–6.94 μg.mL(−1)). With the addition of remifentanil at an effect-site concentration of 5 ng.mL(−1), the EC(50) of propofol required for LMA-Supreme™ insertion was 2.50 ± 0.80 μg.mL(−1) (95 % CI, 1.82–3.17 μg.mL(−1); p < 0.0001). CONCLUSIONS: The propofol requirement for smooth insertion of the LMA-Supreme™ was 60 % less when remifentanil (5 ng.mL(−1)) was co-administered. CLINICAL TRIAL REGISTRATION: Identified as NCT01974648 at www.clinicaltrials.gov. |
format | Online Article Text |
id | pubmed-4595052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45950522015-10-07 Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial Zaballos, Matilde Bastida, Emilia Agustí, Salomé Portas, Maite Jiménez, Consuelo López-Gil, Maite BMC Anesthesiol Research Article BACKGROUND: A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 % (EC(50)) of adults necessary for successful insertion of the LMA-Supreme™ and to examine remifentanil’s effect on propofol requirements. METHODS: Fifty-eight elective patients (aged 18–60 years; ASA (American Society Anaesthesiologists) physical status classification I and II) scheduled for day surgery were randomly assigned to one of two groups: propofol with saline or propofol with remifentanil. Anaesthesia was induced by target-controlled infusion according to predetermined effect-site concentrations of propofol and remifentanil (5 ng.mL(−1)). The EC(50) was calculated using Dixon’s up-and-down method. Ten minutes following drug administration, LMA-Supreme™ insertion was attempted without the use of muscle relaxant drugs. RESULTS: In the propofol + saline group, the EC(50) of propofol required for LMA-Supreme™ insertion was 6.32 ± 0.67 μg.mL(−1) (95 % CI, 5.69–6.94 μg.mL(−1)). With the addition of remifentanil at an effect-site concentration of 5 ng.mL(−1), the EC(50) of propofol required for LMA-Supreme™ insertion was 2.50 ± 0.80 μg.mL(−1) (95 % CI, 1.82–3.17 μg.mL(−1); p < 0.0001). CONCLUSIONS: The propofol requirement for smooth insertion of the LMA-Supreme™ was 60 % less when remifentanil (5 ng.mL(−1)) was co-administered. CLINICAL TRIAL REGISTRATION: Identified as NCT01974648 at www.clinicaltrials.gov. BioMed Central 2015-10-06 /pmc/articles/PMC4595052/ /pubmed/26438179 http://dx.doi.org/10.1186/s12871-015-0115-8 Text en © Zaballos et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zaballos, Matilde Bastida, Emilia Agustí, Salomé Portas, Maite Jiménez, Consuelo López-Gil, Maite Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial |
title | Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial |
title_full | Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial |
title_fullStr | Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial |
title_full_unstemmed | Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial |
title_short | Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial |
title_sort | effect-site concentration of propofol required for lma-supreme™ insertion with and without remifentanil: a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595052/ https://www.ncbi.nlm.nih.gov/pubmed/26438179 http://dx.doi.org/10.1186/s12871-015-0115-8 |
work_keys_str_mv | AT zaballosmatilde effectsiteconcentrationofpropofolrequiredforlmasupremeinsertionwithandwithoutremifentanilarandomizedcontrolledtrial AT bastidaemilia effectsiteconcentrationofpropofolrequiredforlmasupremeinsertionwithandwithoutremifentanilarandomizedcontrolledtrial AT agustisalome effectsiteconcentrationofpropofolrequiredforlmasupremeinsertionwithandwithoutremifentanilarandomizedcontrolledtrial AT portasmaite effectsiteconcentrationofpropofolrequiredforlmasupremeinsertionwithandwithoutremifentanilarandomizedcontrolledtrial AT jimenezconsuelo effectsiteconcentrationofpropofolrequiredforlmasupremeinsertionwithandwithoutremifentanilarandomizedcontrolledtrial AT lopezgilmaite effectsiteconcentrationofpropofolrequiredforlmasupremeinsertionwithandwithoutremifentanilarandomizedcontrolledtrial |